Literature DB >> 19903857

Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation.

Giorgio Cattoretti1, Jonathan Mandelbaum, Nancy Lee, Alicia H Chaves, Ashley M Mahler, Amy Chadburn, Riccardo Dalla-Favera, Laura Pasqualucci, A John MacLennan.   

Abstract

S1P(2) sphingosine 1-phosphate receptor signaling can regulate proliferation, survival, morphology, and migration in many cell types in vitro. Here, we report that S1P(2)(-/-) mice develop clonal B-cell lymphomas with age, such that approximately half of the animals display this neoplasm by 1.5 to 2 years of age. Histologic, immunophenotypic, and molecular analyses revealed a uniform tumor phenotype with features of germinal center (GC)-derived diffuse large B-cell lymphoma (DLBCL). Tumor formation was preceded by increases in GC B cells and CD69(+) T cells, as well as an increased formation of spontaneous GCs, suggesting that S1P(2) loss may promote lymphomagenesis in part by disrupting GC B-cells homeostasis. With the sole exception of rare lung tumors, the effect of S1P(2) gene disruption is remarkably restricted to DLBCL. In humans, 28 of 106 (26%) DLBCL samples were found to harbor multiple somatic mutations in the 5' sequences of the S1P(2) gene. Mutations displayed features resembling those generated by the IgV-associated somatic hypermutation mechanism, but were not detected at significant levels in normal GC B cells, indicating a tumor-associated aberrant function. Collectively, our data suggest that S1P(2) signaling may play a critical role in suppressing DLBCL formation in vivo. The high incidence of DLBCL in S1P(2)(-/-) mice, its onset at old age, and the relative lack of other neoplasms identify these mice as a novel, and potentially valuable, model for this highly prevalent and aggressive human malignancy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903857      PMCID: PMC2973841          DOI: 10.1158/0008-5472.CAN-09-1110

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

2.  Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells.

Authors:  Markus Graeler; Edward J Goetzl
Journal:  FASEB J       Date:  2002-12       Impact factor: 5.191

3.  Bad-deficient mice develop diffuse large B cell lymphoma.

Authors:  Ann M Ranger; Jiping Zha; Hisashi Harada; Sandeep Robert Datta; Nika N Danial; Andrew P Gilmore; Jeffery L Kutok; Michelle M Le Beau; Michael E Greenberg; Stanley J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-22       Impact factor: 11.205

4.  Sphingosine 1-phosphate induces chemotaxis of immature and modulates cytokine-release in mature human dendritic cells for emergence of Th2 immune responses.

Authors:  Marco Idzko; Elisabeth Panther; Silvia Corinti; Anna Morelli; Davide Ferrari; Yared Herouy; Stefan Dichmann; Maja Mockenhaupt; Peter Gebicke-Haerter; Francesco Di Virgilio; Giampiero Girolomoni; Johannes Norgauer
Journal:  FASEB J       Date:  2002-04       Impact factor: 5.191

5.  An essential role for the H218/AGR16/Edg-5/LP(B2) sphingosine 1-phosphate receptor in neuronal excitability.

Authors:  A J MacLennan; P R Carney; W J Zhu; A H Chaves; J Garcia; J R Grimes; K J Anderson; S N Roper; N Lee
Journal:  Eur J Neurosci       Date:  2001-07       Impact factor: 3.386

6.  Dysregulated TCL1 promotes multiple classes of mature B cell lymphoma.

Authors:  Katrina K Hoyer; Samuel W French; Devin E Turner; Mai T N Nguyen; Mathilde Renard; Cindy S Malone; Sonja Knoetig; Chen-Feng Qi; Thomas T Su; Hilde Cheroutre; Randolph Wall; David J Rawlings; Herbert C Morse; Michael A Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-14       Impact factor: 11.205

Review 7.  Lysophospholipid receptors in the nervous system.

Authors:  Rachelle E Toman; Sarah Spiegel
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

8.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

9.  Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme.

Authors:  M Muramatsu; K Kinoshita; S Fagarasan; S Yamada; Y Shinkai; T Honjo
Journal:  Cell       Date:  2000-09-01       Impact factor: 41.582

10.  Bethesda proposals for classification of lymphoid neoplasms in mice.

Authors:  Herbert C Morse; Miriam R Anver; Torgny N Fredrickson; Diana C Haines; Alan W Harris; Nancy L Harris; Elaine S Jaffe; Scott C Kogan; Ian C M MacLennan; Paul K Pattengale; Jerrold M Ward
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

View more
  57 in total

Review 1.  Pathogenesis of diffuse large B cell lymphoma.

Authors:  Wing John C Chan
Journal:  Int J Hematol       Date:  2010-06-29       Impact factor: 2.490

2.  Vascular modulation through exercise improves chemotherapy efficacy in Ewing sarcoma.

Authors:  Miriam B G Morrell; Claudia Alvarez-Florez; Aiqian Zhang; Eugenie S Kleinerman; Hannah Savage; Enrica Marmonti; Minjeong Park; Angela Shaw; Keri L Schadler
Journal:  Pediatr Blood Cancer       Date:  2019-05-28       Impact factor: 3.167

3.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

Authors:  Ryan D Morin; Karen Mungall; Erin Pleasance; Andrew J Mungall; Rodrigo Goya; Ryan D Huff; David W Scott; Jiarui Ding; Andrew Roth; Readman Chiu; Richard D Corbett; Fong Chun Chan; Maria Mendez-Lago; Diane L Trinh; Madison Bolger-Munro; Greg Taylor; Alireza Hadj Khodabakhshi; Susana Ben-Neriah; Julia Pon; Barbara Meissner; Bruce Woolcock; Noushin Farnoud; Sanja Rogic; Emilia L Lim; Nathalie A Johnson; Sohrab Shah; Steven Jones; Christian Steidl; Robert Holt; Inanc Birol; Richard Moore; Joseph M Connors; Randy D Gascoyne; Marco A Marra
Journal:  Blood       Date:  2013-05-22       Impact factor: 22.113

Review 4.  An update on the biology of sphingosine 1-phosphate receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  J Lipid Res       Date:  2014-01-23       Impact factor: 5.922

5.  New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2010-06-02       Impact factor: 0.196

Review 6.  Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy.

Authors:  Richard L Proia; Timothy Hla
Journal:  J Clin Invest       Date:  2015-04-01       Impact factor: 14.808

Review 7.  Germinal centres and B cell lymphomagenesis.

Authors:  Katia Basso; Riccardo Dalla-Favera
Journal:  Nat Rev Immunol       Date:  2015-03       Impact factor: 53.106

Review 8.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

Review 9.  Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.

Authors:  Kenneth C Loh; Dianna Baldwin; Julie D Saba
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

10.  Sphingolipid modulation of angiogenic factor expression in neuroblastoma.

Authors:  Mei-Hong Li; Timothy Hla; Fernando Ferrer
Journal:  Cancer Prev Res (Phila)       Date:  2011-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.